Investors | Radiopharm Theranostics

annual reportS

September 2022

RAD Annual Report June 2022

September 2022

RAD ESG Report 2022

shareholder newsletter

May 2023

Radiopharm Newsletter 1st Quarter 2023

December 2022

Radiopharm Newsletter December 2022

July 2022

Radiopharm Newsletter July 2022

March 2022

Radiopharm Newsletter March 2022 - Meet our CEO in Australia

ANalyst coverage

February 2023

Diamond Equity Research update Valuation at 70 cents per share

December 2022

Diamond Equity Research update Valuation to 70 cents per share

August 2022

Diamond Equity Research increases Valuation to 88 cents per share

June 2022

Bioshares RAD Update 17 June 2022

corporate governance

Radiopharm Theranostics Prospectus and Supplementary Disclaimers

Radiopharm Theranostics Prospectus

Radiopharm Theranostics Supplementary Prospectus

Corporate Governance

corporate policies

Privacy Policy

Sign up to our mailing list.

Receive all the latest news from Radiopharm Theranostics.